Educational Objectives

·            Recognize best practices for managing adverse effects associated with immune checkpoint inhibitor (ICI)-targeted therapy combinations

 

Faculty:

Jacob K. Kettle, PharmD, BCOP

Pharmacy Manager

Ellis Fischel Cancer Center

Department of Pharmacy

University of Missouri Health Care

Columbia, Missouri

 

Faculty, has the following financial relationships with commercial interests to disclose:

Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI

Consultant: Pfizer, Lilly

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-21-438-H01-P. The activity is available for CE credit through December 17, 2022.

This activity is supported by educational grants from Eisai Inc and Exelixis, Inc.

Learn more about your ad choices. Visit megaphone.fm/adchoices